Altitude illness: Update on prevention and treatment

Current Sports Medicine Reports

Volumn 11, Issue 3, 2012, Pages 124-130

  Eide III, Richard P ^a   Asplund, Chad A ^a  

^a EISENHOWER ARMY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETAZOLAMIDE; CATECHOLAMINE; DEXAMETHASONE; FUROSEMIDE; GINKGO BILOBA EXTRACT; HYPOXIA INDUCIBLE FACTOR 1ALPHA; IRON; MAGNESIUM; MEDROXYPROGESTERONE; NIFEDIPINE; NITRIC OXIDE; SALMETEROL; SILDENAFIL; SPIRONOLACTONE; SUMATRIPTAN; TADALAFIL; THEOPHYLLINE; TRIPTAN DERIVATIVE; VASCULOTROPIN;

ALTITUDE ACCLIMATIZATION; ALTITUDE DISEASE; BRAIN BLOOD FLOW; DEHYDRATION; ENVIRONMENTAL EXPOSURE; FATIGUE; HEALTH EDUCATION; HEMATOCRIT; HUMAN; HYPOTHERMIA; HYPOXEMIA; HYPOXIA; INCIDENCE; IRON THERAPY; OXYGEN THERAPY; PROPHYLAXIS; REVIEW; RISK FACTOR;

ACCLIMATIZATION; ACETAZOLAMIDE; ALTITUDE SICKNESS; ANTI-INFLAMMATORY AGENTS; BRAIN EDEMA; DEXAMETHASONE; DIURETICS; HUMANS; OXYGEN; PHOSPHODIESTERASE 5 INHIBITORS; PULMONARY EDEMA;

EID: 84863613860     PISSN: 1537890X     EISSN: 15378918     Source Type: Journal    
DOI: 10.1249/JSR.0b013e3182563e7a     Document Type: Review

References (50)

1. Bailey DM, Bartsch P, Knauth M, Baumgartner RW. Emerging concepts in acute mountain sickness and high-altitude cerebral edema: from the molecular to the morphological. Cell. Mol. Life Sci. 2009; 66:3583-94.
2. Bailey DM, Evans KA, James PE, et al. Altered free radical metabolism in acute mountain sickness: implications for dynamic cerebral autoregulation and blood-brain barrier function. J. Physiol. 2009; 587(Pt 1):73-85.
3. Baillie JK, Thompson AA, Irving JB, et al. Oral antioxidant supplementation does not prevent acute mountain sickness: double blind, randomized placebocontrolled trial. QJM. 2009; 102:341-8.
4. Bartsch P, Bailey DM, Berger MM, et al. Acute mountain sickness: controversies and advances. High Alt. Med. Biol. 2004; 5:110-24. (Pubitemid 39069613)
5. Bartsch P, Maggiorini M, Ritter M, et al. Prevention of high-altitude pulmonary edema by nifedipine. N. Engl. J. Med. 1991; 325:1284-9.
6. Bartsch P, Merki B, Hofstetter D, et al. Treatment of acute mountain sickness by simulated descent: a randomised controlled trial. BMJ. 1993; 306:1098-101. (Pubitemid 23108843)
7. Bartsch P, Swenson ER, Paul A, et al. Hypoxic ventilatory response, ventilation, gas exchange, and fluid balance in acute mountain sickness. High Alt. Med. Biol. 2002; 3:361-76. (Pubitemid 36305489)
8. Basnyat B, Gertsch JH, Johnson EW, et al. Efficacy of low-dose acetazolamide (125 mg BID) for the prophylaxis of acute mountain sickness: a prospective, double-blind, randomized, placebo-controlled trial. High Alt. Med. Biol. 2003; 4:45-52. (Pubitemid 36511798)
9. Basnyat B, Holck PS, Pun M, et al. Spironolactone does not prevent acute mountain sickness: a prospective, double-blind, randomized, placebo-controlled trial by SPACE Trial Group (spironolactone and acetazolamide trial in the prevention of acute mountain sickness group). Wilderness Environ. Med. 2011; 22:15-22.
10. Bates MG, Thompson AA, Baillie JK, et al. Sildenafil citrate for the prevention of high altitude hypoxic pulmonary hypertension: double blind, randomized, placebo-controlled trial. High Alt. Med. Biol. 2011; 12:207-14.
11. Chow T, Browne V, Heileson HL, et al. Ginkgo biloba and acetazolamide prophylaxis for acute mountain sickness: a randomized, placebo-controlled trial. Arch. Intern. Med. 2005; 165:296-301. (Pubitemid 40216282)
12. Dumont L, Mardirosoff C, Soto-Debeuf G, Tassonyi E. Magnesiumand acute mountain sickness. Aviat. Space Environ. Med. 1999; 70:625.
13. Ellsworth AJ, Larson EB, Strickland D. A randomized trial of dexamethasone and acetazolamide for acute mountain sickness prophylaxis.Am. J. Med. 1987; 83:1024-30. (Pubitemid 18098873)
14. Fischer R, Lang SM, Leitl M, et al. Theophylline and acetazolamide reduce sleep-disordered breathing at high altitude. Eur. Respir. J. 2004; 23:47-52. (Pubitemid 38088495)
15. Gertsch JH, Basnyat B, Johnson EW, et al. Randomised, double blind, placebo controlled comparison of ginkgo biloba and acetazolamide for prevention of acute mountain sickness among Himalayan trekkers: the Prevention of High Altitude Illness Trial (PHAIT). BMJ. 2004; 328:797.
16. Ghofrani HA, Reichenberger F, Kohstall MG, et al. Sildenafil increased exercise capacity during hypoxia at low altitudes and at Mount Everest base camp: a randomized, double-blind, placebo-controlled crossover trial. Ann. Intern. Med. 2004; 141:169-77.
17. Hackett PH, Roach RC. High-altitude illness. N. Engl. J. Med. 2001; 345: 107-14. (Pubitemid 32634570)
18. Hackett PH, Yarnell PR, Hill R, et al. High-altitude cerebral edema evaluated with magnetic resonance imaging: clinical correlation and pathophysiology. JAMA. 1998; 280:1920-5. (Pubitemid 28559809)
19. Hannon JP, Chinn KS, Shields JL. Effects of acute high-altitude exposure on body fluids. Fed. Proc. 1969; 28:1178-84.
20. Imray C, Wright A, Subudhi A, Roach R. Acute mountain sickness: pathophysiology, prevention, and treatment. Prog. Cardiovasc. Dis. 2010; 52: 467-84.
21. Jafarian S, Gorouhi F, Salimi S, Lotfi J. Sumatriptan for prevention of acute mountain sickness: randomized clinical trial. Ann. Neurol. 2007; 62:273-7. (Pubitemid 47525403)
22. Sutton JR, Coates G, Houston CS. Hypoxia and Mountain Medicine. 1st ed. Burlington (VT): Queen City Press, 1992.
23. Kamimori GH, Ryan EJ, Otterstetter R, et al. Catecholamine levels in hypoxia-induced acute mountain sickness. Aviat. Space Environ. Med. 2009; 80:376-80.
24. Küpper TE, Strohl KP, Hoefer M, et al. Low-dose theophylline reduces symptoms of acute mountain sickness. J. Travel. Med. 2008; 15:307-14.
25. Leadbetter G, Keyes LE, Maakestad KM, et al. Ginkgo biloba does - and does not - prevent acute mountain sickness. Wilderness Environ. Med. 2009; 20:66-71.
26. Leaf DE, Goldfarb DS. Mechanisms of action of acetazolamide in the prophylaxis and treatment of acute mountain sickness. J. Appl. Physiol. 2007; 102:1313-22. (Pubitemid 46571023)
27. Levine BD, Yoshimura K, Kobayashi T, et al. Dexamethasone in the treatment of acute mountain sickness. N. Engl. J. Med. 1989; 321:1707-13. (Pubitemid 20020546)
28. Luks AM, McIntosh SE, Grissom CK, et al. Wilderness Medical Society consensus guidelines for the prevention and treatment of acute altitude illness. Wilderness Environ. Med. 2010; 21:146-55.
29. Luks AM, Swenson ER. Medication and dosage considerations in the prophylaxis and treatment of high-altitude illness. Chest. 2008; 133:744-55. (Pubitemid 351367385)
30. Maa EH. Hypobaric hypoxic cerebral insults: the neurological consequences of going higher. NeuroRehabilitation. 2010; 26:73-84.
31. MacInnis MJ, Koehle MS, Rupert JL. Evidence for a genetic basis for altitude illness: 2010 update. High Alt. Med. Biol. 2010; 11:349-68.
32. Maggiorini M. Prevention and treatment of high-altitude pulmonary edema. Prog. Cardiovasc. Dis. 2010; 52:500-6.
33. Maggiorini M, Brunner-La Rocca HP, Peth S, et al. Both tadalafil and dexamethasone may reduce the incidence of high-altitude pulmonary edema: a randomized trial. Ann. Intern. Med. 2006; 145:497-506. (Pubitemid 46780953)
34. Maloney J, Wang D, Duncan T, et al. Plasma vascular endothelial growth factor in acute mountain sickness. Chest. 2000; 118:47-52. (Pubitemid 30485488)
35. Muza SR, Beidleman BA, Fulco CS. Altitude preexposure recommendations for inducing acclimatization. High Alt. Med. Biol. 2010; 11:87-92.
36. Rexhaj E, Garcin S, Rimoldi SF, et al. Reproducibility of acute mountain sickness in children and adults: a prospective study. Pediatrics. 2011; 127:e1445-8.
37. Ross RT. The random nature of cerebral mountain sickness. Lancet. 1985; 1: 990-1. (Pubitemid 15124002)
38. Sartori C, Allemann Y, Duplain H, et al. Salmeterol for the prevention of high-altitude pulmonary edema. N. Engl. J. Med. 2002; 346:1631-6. (Pubitemid 34755671)
39. Scherrer U, Rexhaj E, Jayet PY, et al. New insights in the pathogenesis of high-altitude pulmonary edema. Prog. Cardiovasc. Dis. 2010; 52:485-92.
40. Schoene RB. Illnesses at high altitude. Chest. 2008; 134:402-16.
41. Schoene RB, Roach RC, Hackett PH, et al. High altitude pulmonary edema and exercise at 4,400 meters on Mount McKinley. Effect of expiratory positive airway pressure. Chest. 1985; 87:330-3. (Pubitemid 15139960)
42. Schommer K, Wiesegart N, Menold E, et al. Training in normobaric hypoxia and its effects on acute mountain sickness after rapid ascent to 4559 m. High Alt. Med. Biol. 2010; 11:19-25.
43. Singh I, Khanna PK, Srivastava MC, et al. Acute mountain sickness. N. Engl. J. Med. 1969; 280:175-84.
44. Smith TG, Talbot NP, Privat C, et al. Effects of iron supplementation and depletion on hypoxic pulmonary hypertension: two randomized controlled trials. JAMA. 2009; 302;1444-50.
45. Subedi BH, Pokharel J, Goodman TL, et al. Complications of steroid use on Mt. Everest. Wilderness Environ. Med. 2010; 21:345-8.
46. Talbot NP, Smith TG, Privat C, et al. Intravenous iron supplementation may protect against acute mountain sickness: a randomized, double-blinded, placebo-controlled trial. High Alt. Med. Biol. 2011; 12:265-9.
47. van Patot MC, Leadbetter G, Keyes LE, et al. Prophylactic low-dose acetazolamide reduces the incidence and severity of acute mountain sickness. High Alt. Med. Biol. 2008; 9:289-93.
48. Voelkel NF. High-altitude pulmonary edema. N. Engl. J. Med. 2002; 346: 1606-7. (Pubitemid 34755667)
49. Webb JD, Coleman ML, Pugh CW. Hypoxia, hypoxia-inducible factors (HIF), HIF hydroxylases and oxygen sensing. Cell. Mol. Life Sci. 2009; 66: 3539-54.
50. Wright AD, Beazley MF, Bradwell AR, et al. Medroxyprogesterone at high altitude. The effects on blood gases, cerebral regional oxygenation, and acute mountain sickness. Wilderness Environ. Med. 2004; 15:25-31. (Pubitemid 38326086)